Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium
PR Newswire —
SECAUCUS, N.J., Jan. 6, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026...